• Developing global, high-value products for patients with significant unmet medical needs in niche indications

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.


A potential treatment for patients with IgA nephropathy at risk of developing ESRD.


Calliditas shortlisted in two categories at the European Lifestars Awards: Post-IPO Equity Raise of the Year and Deal of the Year (<£500m)